| Literature DB >> 24708296 |
Simone Santoro, Isa Pacios, Sacramento Moreno, Alejandro Bertó-Moran, Carlos Rouco1.
Abstract
Host-pathogen epidemiological processes are often unclear due both to their complexity and over-simplistic approaches used to quantify them. We applied a multi-event capture-recapture procedure on two years of data from three rabbit populations to test hypotheses about the effects on survival of, and the dynamics of host immunity to, both myxoma virus and Rabbit Hemorrhagic Disease Virus (MV and RHDV). Although the populations shared the same climatic and management conditions, MV and RHDV dynamics varied greatly among them; MV and RHDV seroprevalences were positively related to density in one population, but RHDV seroprevalence was negatively related to density in another. In addition, (i) juvenile survival was most often negatively related to seropositivity, (ii) RHDV seropositives never had considerably higher survival, and (iii) seroconversion to seropositivity was more likely than the reverse. We suggest seropositivity affects survival depending on trade-offs among antibody protection, immunosuppression and virus lethality. Negative effects of seropositivity might be greater on juveniles due to their immature immune system. Also, while RHDV directly affects survival through the hemorrhagic syndrome, MV lack of direct lethal effects means that interactions influencing survival are likely to be more complex. Multi-event modeling allowed us to quantify patterns of host-pathogen dynamics otherwise difficult to discern. Such an approach offers a promising tool to shed light on causative mechanisms.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24708296 PMCID: PMC4021418 DOI: 10.1186/1297-9716-45-39
Source DB: PubMed Journal: Vet Res ISSN: 0928-4249 Impact factor: 3.683
Myxoma Virus model-selection best models
| Survival | Age*sex | 58; 6694.55; 6813.05; 0.66 | |
| | | Age | 56; 6700.78; 6815.10; 0.23 |
| | | Age*immun | 58; 6699.49; 6817.99; 0.06 |
| | Seroconversion | Sex*immun | 62; 6691.23; 6818.08; 0.92 |
| Survival | Age*sex*immun | 53; 4733.87; 4053.88; 0.88 | |
| | | Age*immun | 49; 4750.48; 4059.29; 0.06 |
| | Serocoversion | Sex*immun | 53; 4733.87; 4053.88; 1 |
| Survival | Immun | 48; 3664.89; 3764.20; 0.69 | |
| | | Age*sex*immun | 54; 3654.65; 3766.85; 0.18 |
| | | Sex*immun | 50; 3664.83; 3768.43; 0.08 |
| | Seroconversion | Immun | 52; 3656.86; 3764.76; 0.71 |
| Sex*immun | 54; 3654.65; 3766.85; 0.25 |
np, number of parameters; Dev, Deviance; QAICc, Quasi-Akaike Information Criterion corrected for over-dispersion; w, Akaike weight (support of the current model with respect to the candidate set of models). Model notation: immun, the immunological status: for survival it means a different survival rate according to immunological status whereas for seroconversion it means that seroconversion rate from seropositive to seronegative is different than seroconversion from seronegative to seropositive; age, juveniles vs. adults; sex, females vs. males.
For each analysis, only models accounting for more than 90% of cumulative Akaike weights are reported.
Figure 1Average monthly survival probability according to serological status (to MV and RHDV), age and gender in the three enclosures (E1, E2, and E3). Only estimates related to effects selected in models with lowest QAICc are shown (e.g. if sex effect on survival was found to be negligible by model selection, one common estimate is shown for both males and females). Estimates with 95% confidence intervals are shown. Notation: juv, juvenile; SN, seronegative; SP, seropositive; mal, males; fem, females.
Rabbit Hemorrhagic Disease Virus model-selection best models
| Survival | Age*sex*immun | 83; 6518.66; 6689.61; 0.73 | |
| | | Sex*immun | 79; 6530.35; 6692.83; 0.15 |
| | | Immun | 77; 6535.99; 6694.24; 0.07 |
| | Seroconversion | Immun | 81; 6519.89; 6686.59; 0.74 |
| | | Sex*immun | 83; 6518.66; 6689.61; 0.16 |
| Survival | Age*immun | 49; 4724.47; 4037.61; 0.62 | |
| | | Age*sex*immun | 53; 4718.07; 4040.71; 0.13 |
| | | Age | 47; 4733.35; 4040.81; 0.13 |
| | | Age*sex | 49; 4729.07; 4041.44; 0.09 |
| | Serocoversion | Sex*immun | 53; 4718.07; 4040.71; 0.82 |
| | | Sex | 51; 4726.87; 4043.82; 0.17 |
| Survival | Age*immun | 42; 3830.64; 3917.17; 0.42 | |
| | | Age | 40; 3835.32; 3917.62; 0.34 |
| | | Immun | 40; 3837.85; 3920.15; 0.09 |
| | | Age*sex | 42; 3834.10; 3920.63; 0.07 |
| | Seroconversion | Sex*immun | 46; 3827.61; 3922.65; 0.54 |
| Immun | 44; 3832.35; 3923.13; 0.43 |
See Table 1 footnote for notations used.
Figure 2Myxoma and Rabbit Hemorrhagic Disease Virus seroconversion rates in the three enclosures (E1, E2, and E3). Estimates with 95% confidence intervals are shown. Notation: SN → SP, average monthly rate at which individuals change their immunological status from seronegative to seropositive; SP → SN, from seropositive to seronegative; mal, males; fem, females.
Effect of rabbit density on Initial State (seroprevalence of MV and RHDV)
| 4.65; 0.07; 0.66 | 5.11; 0.06; 0.73 | |
| 0.25; 0.63; 0.03 | 0.80; 0.4; 0.11 | |
| 5.01; 0.06; 0.71 | 2.94; 0.13; 0.42 |
From left to right: the Fisher–Snedecor statistic (F1,7 for Initial State and F1,6 for the others), P-value (in bold if < 0.1), and R2. All statistics were computed following the ANODEV procedure. Myxo, myxoma virus; RHD, Rabbit Hemorrhagic Disease Virus; Prev, prevalence.